GLPwatch
The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.
Lancet · 2025
Last updated 2026-08-24| Journal | Lancet, 2025 |
|---|---|
| Citations | 1 |
| Molecules | pemvidutide |
| Conditions studied | Mash |
Full record and abstract on PubMed 41352959 ↗
Related research
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.